Watch S1, EP37: The Disruptors with Fubo for $0 Today
In Part 1, Lawrence Calcano shares how he left Goldman Sachs to build iCapital, overcame the early chicken-and-egg challenge, and transformed alternative investing for financial advisors. Learn the lessons, mindset, and vision behind one of finance.
In Part 1, Lawrence Calcano shares how he left Goldman Sachs to build iCapital, overcame the early chicken-and-egg challenge, and transformed alternative investing for financial advisors. Learn the lessons, mindset, and vision behind one of finance.
How to watch
More episodes
The Disruptors
S1, EP37 "The Disruptors"In Part 1, Lawrence Calcano shares how he left Goldman Sachs to build iCapital, overcame the early chicken-and-egg challenge, and transformed alternative investing for financial advisors. Learn the lessons, mindset, and vision behind one of finance.
The Disruptors
S1, EP41 "The Disruptors"In Part 1 Bruce Lee sits down with Heather Domi. She shares how she became an accidental New Yorker, what she learned from selling major new development projects, why she helped launch NYRAC, and how Domi Data helps buyers, sellers and agents better.
The Disruptors
S1, EP40 "The Disruptors"In Part 2, Bruce Lee sits down and speaks with Marti Romances, the co-founder of Territory Studio in San Francisco, the creative studio behind the screen interfaces in films like Prometheus, The Martian and Avengers.
The Disruptors
S1, EP32 "The Disruptors"Bruce sits down with Thomas Cahill to discuss his unique journey from the laboratory to the forefront of life sciences investing, with advanced degrees from Duke University and a foundation in chemistry.
The Disruptors
S1, EP36 "The Disruptors"Thomas Cahill dives deeper into the venture creation model that has made Newpath Partners a force in biotechnology; Tom is a founder, investor and board member across numerous groundbreaking healthcare companies.
The Disruptors
S1, EP32 "The Disruptors"Bruce sits down with Thomas Cahill to discuss his unique journey from the laboratory to the forefront of life sciences investing, with advanced degrees from Duke University and a foundation in chemistry.
